References
- Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood109(5), 1878–1886 (2007).
- Ng AK, Bernardo MP, Weller E et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J. Clin. Oncol.20(8), 2101–2108 (2002).
- Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S. Cardiac glycosides and breast cancer. Lancet1(8115), 563 (1979).
- Stenkvist B. Is digitalis a therapy for breast carcinoma? Oncol. Rep.6(3), 493–496 (1999).
- Dricu A, Wang M, Hjertman M et al. Mevalonate-regulated mechanisms in cell growth control: role of dolichyl phosphate in expression of the insulin-like growth factor-1 receptor (IGF-1R) in comparison to Ras prenylation and expression of c-myc. Glycobiology7(5), 625–633 (1997).
- Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res.68(7), 2375–2383 (2008).
- Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood101(9), 3628–3634 (2003).
- Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol.55(3), 213–220 (2010).
- Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J. Am. Coll. Cardiol.48(11), 2258–2262 (2006).
- Thaker PH, Han LY, Kamat AA et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med.12(8), 939–944 (2006).
- Palm D, Lang K, Niggemann B et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β-blockers. Int. J. Cancer118(11), 2744–2749 (2006).
- Yang EV, Sood AK, Chen M et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res.66(21), 10357–10364 (2006).
- Lever AF, Hole DJ, Gillis CR et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet352(9123), 179–184 (1998).
- Friis S, Sørensen HT, Mellemkjaer L et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer92(9), 2462–2470 (2001).
- Greco S, Muscella A, Elia MG et al. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor receptor in breast cancer cells. J. Cell. Physiol.196(2), 370–377 (2003).
- Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol. Metab.16(7), 293–299 (2005).
- Anandanadesan R, Gong Q, Chipitsyna G, Witkiewicz A, Yeo CJ, Arafat HA. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J. Gastrointest. Surg.12(1), 57–66 (2008).
- Suganuma T, Ino K, Shibata K et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res.11(7), 2686–2694 (2005).
- Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol.11(7), 627–636 (2010).
- Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the renin–angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res.68(22), 9112–9115 (2008).